RICHARD CRAVER Winston-Salem Journal

A new Labcorp technique for early detection of Alzheimer’s disease for adults ages 50 and older has become available nationwide, the Burlington company announced recently.

The Food and Drug Administration has authorized the use of the blood-based in-vitro diagnostic test that works by testing the amyloid plaques associated with the disease in certain patients.

The test has been developed by Fujirebio Diagnostics Inc.

The test is being focused on specialized care settings with patients showing potential signs and symptoms of cognitive decline.

“It is not intended as a screening or stand-alone diagnostic test and must be interpreted in conjunction with other clinical information of the patient,” Labcorp cautioned.

An estimated 6.7 million Americans

See Full Page